LOGIN  |  REGISTER
Recursion
Chimerix

Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2024 Results on July 17, 2024

June 26, 2024 | Last Trade: US$365.96 0.52 -0.14

INDIANAPOLIS / Jun 26, 2024 / Business Wire / Elevance Health (NYSE: ELV) will release second quarter 2024 financial results on July 17, 2024, at 6:00 a.m. Eastern Daylight Time (“EDT”). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers:

  • 888-947-9963 – Access Code - 3972058 (Domestic)
  • 312-470-0178 – Access Code - 3972058 (International)
  • 800-391-9851 – No Access Code (Domestic Replay)
  • 203-369-3268 – No Access Code (International Replay)

The replay will be available from 11:30 a.m. EDT on July 17, 2024, until the end of the day on August 17, 2024. The call will also be available through a live webcast at www.elevancehealth.com under the “Investors” link. You may also access the webcast here. A webcast replay will be available following the call.

About Elevance Health, Inc.

Elevance Health is a lifetime, trusted health partner whose purpose is to improve the health of humanity. The company supports consumers, families, and communities across the entire healthcare journey – connecting them to the care, support, and resources they need to lead better lives. Elevance Health’s companies serve approximately 115 million consumers through a diverse portfolio of industry-leading medical, pharmacy, behavioral, clinical, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on X and Elevance Health on LinkedIn.

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB